Why LifeMD downturn was an ‘overreaction’

Eli Lilly (LLY) is launching a digital healthcare experience, which will allow patients to directly order medications from the manufacturer — including obesity treatment drugs — causing telehealth companies to see a downtrend in share prices. Some of these companies include Hims & Hers (HIMS), LifeMD (LFMD), and Medifast (MED). LifeMD Co-Founder and CEO Justin Schreiber and Medifast CEO Dan Chard join Yahoo Finance to discuss their respective company's stock and why they believe that it was an "overreaction" to the news. "It's really important to note that there's no difference in price for patients that choose to go directly to Lilly with the LillyDirect program," Schreiber says. "Our providers, or any providers in the country, can actually send scripts to this program, so I think it could help our patients access drugs when they can't find them at a neighborhood pharmacy. " For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino.